Related Experiment Video
Updated: Apr 14, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.6K
Pharmacogenomics of cyclooxygenases
José A G Agúndez1, Miguel Blanca, José A Cornejo-García
1Department of Pharmacology, University of Extremadura, Cáceres, Spain.
Pharmacogenomics
|April 29, 2015
Summary
Genetic variations in cyclooxygenase (COX) genes (PTGS1 and PTGS2) influence disease risk and drug reactions. These PTGS gene variations are linked to colorectal cancer and stroke, especially when interacting with NSAIDs and environmental factors.
Area of Science:
- Pharmacogenomics
- Molecular Biology
- Genetics
Background:
- Cyclooxygenases (COX-1 and COX-2) are crucial enzymes in physiological and pathological processes.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) exert many adverse effects through COX inhibition.
- Genetic variations in PTGS1 and PTGS2 genes are implicated in disease susceptibility and drug response.
Purpose of the Study:
- To analyze major variations in PTGS1 and PTGS2 genes, including allele frequencies, functional impacts, and population genetics.
- To catalog current clinical associations of PTGS gene variations.
- To suggest future research directions in this field.
Main Methods:
- Review and analysis of major variations in PTGS1 and PTGS2 genes.
- Examination of allele frequencies, functional consequences, and population genetics.
- Compilation of data from case-control studies and genome-wide association studies (GWAS).
Main Results:
- PTGS gene variations are significantly associated with colorectal cancer and stroke risk.
- Single nucleotide polymorphisms (SNPs) in PTGS genes often interact with NSAID use, diet, and environmental factors.
- Established an updated catalog of PTGS clinical associations.
Conclusions:
- Genetic variability in PTGS genes plays a role in the risk and progression of diseases like colorectal cancer and stroke.
- Understanding PTGS gene variations is crucial for predicting NSAID-related adverse drug reactions.
- Further research is warranted to fully elucidate the complex interactions between PTGS genotypes, environmental factors, and clinical outcomes.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
228
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
228
01:27Pharmacogenetics of Drug Metabolism: Overview
150
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
150
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
126
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
01:29Pharmacogenomics: Identification of New Drug Targets
92
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
01:29Pharmacogenetics and Pharmacogenomics: Overview
180
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
180
01:27Principles of Pharmacogenetics: Types of Genetic Variants
113
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
113